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IBÁÑEZ ET AL. 2525Aims: To estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation
and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries.
Methods: Longitudinal drug utilization study from January 2008 to December 2015. A common protocol approach was
applied. Annual period incidences and direct standardisation by age and sex were performed. Dose adjustment related to
change in age and by renal function as well as concomitant use of potentially interacting drugs were assessed.
Results: A total of 186 405 new DOAC users (age ≥18 years) were identified. Standardized incidences varied from 1.93–
2.60 and 0.11–8.71 users/10 000 (2011–2015) for dabigatran and rivaroxaban, respectively, and from 0.01–8.12
users/10 000 (2012–2015) for apixaban. In 2015, the DOAC incidence ranged from 9 to 28/10 000 inhabitants in SIDIAP
(Spain) and DNR (Denmark) respectively. There were differences in population coverage among the databases. Only 1 data-
base includes the total reference population (DNR) while others are considered a population representative sample (CPRD,
BIFAP, SIDIAP, EGB, Mondriaan). They also varied in the type of drug data source (administrative, clinical). Dose adjustment
ranged from 4.6% in BIFAP (Spain) to 15.6% in EGB (France). Concomitant use of interacting drugs varied between 16.4%
(SIDIAP) and 70.5% (EGB). Cardiovascular comorbidities ranged from 25.4% in Mondriaan (The Netherlands) to 82.9% in
AOK Nordwest (Germany).
Conclusion: Overall, apixaban and rivaroxaban increased its use during the study period while dabigatran decreased. There
was variability in patient characteristics such as comorbidities, potentially interacting drugs and dose adjustment. (EMA/2015/
27/PH).
KEYWORDS
anticoagulants, arrhythmia, cardiovascular, drug utilization, pharmacoepidemiology1 | INTRODUCTION
Patients with atrial fibrillation have long been treated with vitamin K
antagonists for the prevention of cerebral embolism. The newer direct
oral anticoagulants (DOACs) have been approved by the European
Union since 2008. The first was dabigatran (2008), a thrombin inhibi-
tor; this was followed by rivaroxaban (2008), apixaban (2011) and
edoxaban (2015), factor Xa inhibitors. The first approval for the pre-
vention of stroke and systemic embolism in patients with nonvalvular
atrial fibrillation (NVAF) was for dabigatran in 2011 (Table S1). DOACs
are currently recommended by the European Society of Cardiology as
first‐line anticoagulant treatment in NVAF, without mitral stenosis or
mechanical heart valves.1
The incidence of NVAF is estimated to be 3% in adults aged 20 or
older, increasing with age,2,3 with incidence of 12% in females and
14% in males aged over 75 years.3 Atrial fibrillation is associated with
increased cardiovascular morbidity, such as heart failure and stroke.4,5
Clinical trials have shown that both vitamin K antagonists and DOACs
reduce stroke and mortality in AF patients.5,6 Utilization of DOACs for
stroke prevention in NVAF and their effectiveness and safety in clini-
cal practice have been assessed in several European countries.7-13
However, little is known about their use beyond clinical trial condi-
tions, especially in patients with hepatic or renal impairment. Findings
from 2 studies from USA and Australia showed that inappropriate
dosing occurred among patients with renal failure, and there is still
uncertainty about appropriate dosing in these patients.14,15 Inaddition, the very elderly, who may be at increased risk of adverse
effects with inappropriate DOAC use, are poorly represented in
clinical trials.16,17
This cross‐national comparison drug utilization study, using longi-
tudinal data from 8 electronic health care databases in 6 European
countries, uses a common protocol to characterize DOAC users in a
real‐world setting in order to establish the effectiveness of existing
risk minimization measures and their appropriateness for the future.
Its objectives are to assess incidence of use and user characteristics,
including concomitant exposure to potentially interacting medicines
and rates of dose adjustment related to age or renal impairment.2 | METHODS
2.1 | Data sources
We conducted a longitudinal drug utilization study in 6 countries
between January 2008 and December 2015. Data were retrieved
from the following 8 databases: (i) the Dutch Mondriaan project,
which includes the Julius General Practitioner Network (JHN) data-
base18; (ii) the Danish National Registries (DNR), which includes the
Danish National Patient Register, Danish National Prescription Registry
and Danish Civil Registration System19-21; (iii) the AOKNordwest data-
base22,23, Germany; (iv) the Bavarian Association of Statutory Health
Insurance Physicians database, referred to here as Bavarian CD,
What is already known about this subject
• An increase in the number of direct oral anticoagulant
drug (DOAC) users with a diagnosis of nonvalvular atrial
fibrillation (NVAF) has been reported since their
marketing in several national/regional studies in Europe,
IBÁÑEZ ET AL.2526Germany24; (v) the Base de datos para la Investigación
Farmacoepidemiológica en Atención Primaria (BIFAP), Spain25; (vi) the
Information System for the Development of Research in Primary Care
(SIDIAP), Catalonia, Spain26; (vii) the Clinical Practice Research
Datalink (CPRD), UK27,28; (viii) The Echantillon Généraliste de
Bénéficiaires (EGB), France.29 The databases characteristics are
described inTable 1.
but no cross‐national comparison is available.
• The characteristics of DOAC users related to NVAF have
been described but concomitant use of potentially
interacting drugs is rarely reported. DOAC users are
usually younger than 75 years, male and 20% of DOAC
users with NVAF receive dose adjustment related to
renal function.
What this study adds
• Overall DOAC incidences varied from 1.93 to 2.60 and
0.11 to 8.71 users/10 000 (2011–2015) for dabigatran
and rivaroxaban, respectively, and from 0.01 to 8.12
users/10 000 (2012–2015) for apixaban.
• In 2015, the new user DOAC incidence ranged from 9 to
28/10 000 inhabitants 18 years and older in SIDIAP
(Catalonia, Spain) and DNR (Denmark) databases
respectively, this being higher in men than in women
and in those older than 75 years.
• Concomitant use of contraindicated or potentially
interacting drugs varied between 16.4% (SIDIAP) and
70.5% (EGB). Dose adjustment related to age or renal
function varied from 4.6% (BIFAP, Spain) to 15.6%
(EGB, France).2.2 | Study population
The study population was defined as all new users (age ≥18 years) of
the DOACs of interest (dabigatran, rivaroxaban, apixaban). Only those
patients with a diagnosis of NVAF (see codes in supplementary mate-
rial, Table S2) were included. A common protocol was applied for data
extraction and analysis (EU PASS Register No: 16014) for each data-
base.30 Results were blinded to each database lead until the analysis
was completed.
New users were defined as patients initiating DOAC during the
study period without any use of DOAC for at least 365 days prior to
the index date (date of first DOAC prescription). Flow charts for
patient inclusion for each database are shown in Figure S1.
Patients registered in the database <1 year (365 days) before the
index date and patients with a history of valvular atrial fibrillation on
index date or any time prior to initiating DOACs were excluded.
Follow‐up of each patient was until therapy switch, discontinuation
or end of study, whichever came first. Switchers were defined as
patients with a subsequent prescription of another type of (D)OAC,
within the first treatment episode. Discontinuers were defined as
patients who did not receive subsequent DOACs within 30 days fol-
lowing the theoretical end date of the prior DOAC.
As DOACs can be prescribed for indications other than NVAF, a
sensitivity analysis was performed excluding patients with multiple
potential DOAC indications in a ± 3 month period around the first
DOAC prescription.2.3 | Ethical approval
Participants in each country had study approval from the correspond-
ing data owners. No other requirement was required since anonymized
data were used. Additionally, the study protocol was revised and
approved by an internal European Medicines Agency expert panel.2.4 | Outcomes
The main outcome was assessing incidence of DOAC use in patients
with NVAF during the study period.
Annual period incidences are estimated and defined as the number
of new users during the year of interest, divided by the total number
of patients in the database at midyear (1 July).
Secondary aims were to assess concomitant use of interacting
drugs, defined as any prescription of a potentially interacting medicinal
product as indicated in the Summary of Product Characteristics(SmPC) during the first DOAC treatment episode of each patient. A list
of the concomitant interacting drugs considered in the SmPC is given
in eSupplementary Material (Table S3). A treatment episode was
defined as series of prescriptions for a DOAC, independent of dose
changes, considering a gap of up to 30 days, constructed according
to the method of Gardarsdottir et al.31
Furthermore, the occurrence of dose adjustment, defined as
changing from 1 tablet strength to another strength of the same active
substance, was assessed during the first treatment episode.2.5 | Analysis
The analysis is descriptive and stratified by database, individual
DOAC, age group (<75, 75–79, ≥80 years), sex and calendar year.
The baseline characteristics (demographics [sex, age]), comorbidi-
ties, chronic kidney disease (CKD), renal function, laboratory data
when available, hepatic impairment, previous major haemorrhagic epi-
sodes, previous cardiovascular events (see codes in Table S4) and
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IBÁÑEZ ET AL. 2529concomitant exposure to potentially interacting medicines of DOAC
users are presented as absolute number and percentages for each
variable.
For all databases, annual period incidences, with direct
standardisation by age and sex was performed based on the European
standard population corresponding to each year analysed.32 An inci-
dence percentage change in DOAC users with NVAF is given in com-
parison to the first calendar year when NVAF became an approved
indication for use (2012 for dabigatran and rivaroxaban, 2013 for
apixaban). However, in the EGB database, DOAC percentage change
was assessed for 2013–2014 since these are the calendar years with
complete information. In addition, a percentage change of the stan-
dardized incidence, weighted by the database populations, was calcu-
lated from the first to the last calendar year of use.
Percentage of new DOAC users exposed to potentially interacting
medication is expressed as the absolute number and percentage of the
total DOAC users. Dose adjustment is expressed as the percentage of
patients with adjusted dosage following the requirements of the
SmPC and presented either related to change in age or renal function,
as indicated in the SmPC.2.6 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY,33 and are permanently archived in the Concise Guide to
PHARMACOLOGY 2017/18.343 | RESULTS
3.1 | New users
A total of 186 405 new DOAC users (age ≥18 years) with NVAF were
identified during the study period.
Of all new DOAC users, 91 804 (49%), 52 495 (28%) and 42 106
(22%) received rivaroxaban, dabigatran and apixaban, respectively.3.2 | Baseline characteristics
Most of the users were age 75 years or older (48.8% in Mondriaan
to 60.8% in BIFAP). The mean age ranged from 69.3; SD 11.3
(Mondriaan) to 75.7; SD 10.4 years (BIFAP) (Table 2).
Users were most frequently male (range 52.3–58.9%), except in
the AOK and Bavarian CD databases where the opposite was found
(range 46.4–47.7%).
The proportion of patients with comorbidities ranged from 31.1%
(Mondriaan) to 87.3% (AOK). Most frequent were previous cardiovas-
cular events (25.4% in Mondriaan to 82.9 and 76.7% in AOK and
Bavarian CD, respectively).The number of patients with acute or chronic kidney disease, iden-
tified through diagnosis codes, ranged from 0% in the Mondriaan to
24.1% in the Bavarian CD databases. Assessment of laboratory values
with moderately reduced kidney function (Mondriaan, BIFAP, SIDIAP
and CPRD) showed a range from 3.0% (Mondriaan) to 22.6% (CPRD).
DOAC users with severely or very severely reduced renal function
were very uncommon in these databases. However, the proportion
of unregistered information was usually high (range: 3.4% in CPRD
to 77.9% in BIFAP; Table S5).3.3 | Incidence
During this period, overall DOAC incidence increased (Figure 1).
Standardized incidences varied from 1.93–2.60 and 0.11–8.71
users/10 000 (2011–2015) for dabigatran and rivaroxaban, respec-
tively, and from 0.01–8.12 users/10 000 (2012–2015) for apixaban
(Table 3). Apixaban displayed the highest standardized incidence per-
centage change from the first year of use following approval in
NVAF to the final year studied (543.2%), followed by rivaroxaban
(100.2%; Figure 1). This was mainly driven by a sharp increase in
EGB. The standardized percentage incidence change for this first cal-
endar year compared to the previous year was maximum in EGB
(10 550.0%) and minimum in Bavarian CD (218.6%); values compar-
ing for 2014 and 2015 were maximum in Mondriaan (868.5%) and
minimum in SIDIAP (35.1%).The percentage for rivaroxaban
increased in all databases during the first calendar year of use,
except in EGB, with the greatest increase in CPRD (120.9%); a
decrease was seen in the 2 German databases and EGB in 2014–
2015 (Table 4).
The standardized figures show that the incidence of dabigatran
clearly increased in most databases from 2010 to 2012, with the
highest value in the DNR (15.5 new users per 10 000). The CPRD
and Mondriaan figures increased slightly at the end of the study
period. The apixaban standardized incidence increased across
2013–2015 in all databases. The maximum value was observed in
the DNR database in 2015 (13.6 new users per 10 000). The
rivaroxaban standardized incidence increased over time in all data-
bases since its arrival on the market, except in EGB; however, it
started to decrease in Bavarian CD in 2014 and AOK in 2015. The
Bavarian CD database presented the highest rivaroxaban standard-
ized incidence in 2013 (17.5 new users per 10 000). Rivaroxaban
showed the highest annual incidence values in the 2012–2015
period in all databases except in the DNR (Figure 2; Tables S6–S9).
The DOAC incidence increased in males and females across the
study period in most databases, especially in those over 75 years,
whose incidences were higher than those, men and women, younger
than 75 years (Figures S2–S4).
In 2015, the incidence of DOAC use ranged from 8.6 per 10 000 in
SIDIAP to 27.6 per 10 000 in DNR (Table S6), with a higher incidence
in men than in women.
Figure 3 shows the incidence data for all DOACs, per database and
per year, for the whole study period.
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FIGURE 1 Distribution of the total
standardized incidence by individual direct
oral anticoagulant (DOAC; 2011–2015)
TABLE 3 Standardized incidences by individual direct oral antico-
agulant (DOAC) per year (new users per 10 000 people)
DOAC 2010 2011 2012 2013 2014 2015
Dabigatran 0.10 2.60 5.33 4.98 3.49 1.93
Rivaroxaban 0.06 0.11 4.35 8.77 8.85 8.71
Apixaban 0.00 0.00 0.01 1.26 4.99 8.12
IBÁÑEZ ET AL. 25313.4 | Concomitant use of potentially interacting
drugs
The proportion of patients who received an interacting drug during
the first treatment episode ranged from 16.4% (SIDIAP) to 70.5%
(EGB). Concomitant use of contraindicated anticoagulants variedTABLE 4 Standardized incidence percentage change in direct oral antico
(NVAF) in the time periods for the first and last calendar year of use after
Incidence percentage change for the first
calendar year of use after NVAF approvala Incidence pe
Dabigatran
(%)
Apixaban
(%)
Rivaroxaban
(%)
Dabigatran
(%)
Mondriaan −22.93 833.97 2397.26 32.54
NRD −4.58 268.27 266.94 −63.54
AOK Nordwest −8.04 313.13 98.40 −35.54
Bavarian Claims −18.43 218.61 67.96 ‐ 41.56
BIFAP −15.02 712.82 227.42 −6.08
SIDIAP −7.13 462.60 247.88 −5.80
CPRD 80.98 774.46 732.89 3.55
EGB −69.55 10 550.0 −32.33 −56.37
aData for dabigatran and rivaroxaban are calculated for 2012–2013. Data for ap
are calculated for 2013–2014 in EGB.between 0.4% (CPRD) and 24.3% (EGB). Nonsteroidal anti‐
inflammatory drugs (NSAIDs) varied from 4.3% (Mondriaan) to
26.0% (Bavarian CD) and antiplatelet drugs from 1% (SIDIAP) to
18.1% (EGB). The most frequent interacting drugs were heparins in
AOK, BIFAP and Bavarian CD (8.4, 10.4 and 12.1%, respectively),
amiodarone in SIDIAP, DNR and EGB databases (5.7, 6.2 and
42.2%, respectively) and verapamil in Mondriaan (4.1%; Table 5).3.5 | Dose adjustment
The information on dose adjustment was available in BIFAP, SIDIAP,
CPRD and EGB, varying from 4.6% in BIFAP to 15.6% in EGB. The
proportion of dose adjustments related to changes in renal function
or age was <1% in the 3 databases where this information wasagulant new users with a diagnosis of nonvalvular atrial fibrillation
NVAF indication approval (2012–2015)
rcentage change 2014–2015
Incidence percentage change from
the first calendar year of use to 2015
Apixaban
(%)
Rivaroxaban
(%)
Dabigatran
(%)
Apixaban
(%)
Rivaroxaban
(%)
868.50 63.36 11.52 8945.51 21 048.75
60.94 42.41 −73.56 492.68 418.75
80.03 −12.89 −66.09 643.75 74.60
47.54 −24.18 −74.38 370.09 14.99
52.37 12.50 −32.81 1138.46 320.97
35.13 27.75 −26.43 660.23 480.62
180.91 120.90 88.31 2356.46 4902.39
162.44 −16.21 −86.72 27850.0 −43.30
ixaban are calculated for 2013–2014 in all databases. Data for each DOAC
FIGURE 2 Standardized incidences by individual direct oral
anticoagulant in each database
IBÁÑEZ ET AL.2532
FIGURE 3 Standardized and crude incidence for all direct oral
anticoagulants per year and database
IBÁÑEZ ET AL. 2533available (BIFAP, SIDIAP and CPRD). In the Mondriaan database
there were no dose changes recorded. DNR, AOK and
Bavarian CD databases do not have this information registered
(Table S5).3.6 | Sensitivity analysis
Results from the main analysis were compared with results from
patients with only NVAF diagnosis. The total number of patients
treated with DOACs decreased slightly, but the proportions of the
individual DOAC were stable.
Regarding renal function at baseline and dose adjustment, the
numbers were quite similar. The percentage of concomitant
interacting medications increased in SIDIAP database both for all
DOACs and individual DOACs. The percentage of previous cardiovas-
cular events was lower for all DOACs across all databases and the
overall percentage of previous haemorrhagic events was similar
(Tables S10–S12).4 | DISCUSSION
Using a common protocol, we assessed the incidence of DOAC use
during 2009–2015 and the characteristics of 186,405 users from 8
health care databases in 6 European countries (2008–2015). To our
knowledge this is the first cross‐national drug utilization study provid-
ing the incidence of DOAC use in NVAF patients at a national/regional
level, across several European countries. Only a few, single country
European studies with similar inclusion criteria have been published,
which only provide number of DOAC users rather than incidence
figures.10,12,35,36
During the study period, the overall incidence of DOAC
user increased, except in the EGB database; the individual DOAC
with the highest increase was apixaban followed by rivaroxaban.
The largest incidence increase was for apixaban in the EGB. It was
maximum for apixaban in the first calendar year of use in EGB
(10 550.0) and minimum in Bavarian (218.6) while the values for
2014–2015 were maximum in Mondriaan (868.5) and minimum in
SIDIAP (35.1). The striking increase for apixaban in EGB is due to
the fact that its use was very low in 2013. In 2015, the incidence
of DOAC use ranged from 8.7 per 10 000 in SIDIAP to 27.6 per
10 000 in DNR, with a higher incidence in men and in those older
than 75 years.
The differences in incidence across the databases might be
explained by the high proportion of previous cardiovascular events
in AOK, Bavarian CD and DNR databases (82.9, 76.7 and 65.0%,
respectively), which may result in higher incidence of NVAF in these
populations. These results correlate well with the distribution of hos-
pital discharges for cardiovascular and cerebrovascular diseases in
these countries.37
Furthermore, differences in incidence could arise from the charac-
teristics of the databases such as: prescription vs dispensing databases
(DOACs prescribed are not necessarily dispensed), inclusion of
prescriptions from specialists (although we do not expect differences
in the management of NVAF between primary and specialist care
since the European guidelines do not differentiate), population
coverage (DNR is the only national database), different prescribing
patterns in different countries, health services characteristics and their
reimbursement policies, publication of guidelines (local or European),
media and marketing policies.9,38
Several national/regional studies have reported increases in the
number of DOAC users, despite the NVAF population used differing
from ours.9,10,39,40 The incidence increased in both the males and
females across the study period in most databases. More specifically,
incidence was higher in males than in females, since NVAF is more
common in men.10,35,41,424.1 | Incidence of individual DOACs
Overall, rivaroxaban presented the highest incidence figures, except in
the DNR, followed by apixaban and dabigatran. The initial steep
increase in rivaroxaban and apixaban incidence observed in most of
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IBÁÑEZ ET AL. 2535the databases appeared by the end of 2011 and 2012 respectively,
after approval for stroke prevention.43 This sharp increase was not
observed for dabigatran as clearly in any of the databases. Other stud-
ies have shown a steep increase in users for each DOAC after their
marketing.36,394.2 | Demographic characteristics
Themean age of our study population reflected other European studies
on users of DOAC with NVAF, despite varying inclusion
criteria.10,12,35,36,39,41,44 In line with other studies, we found that most
of the users were older than 75 years, except in Mondriaan and DNR
databases.10,12,40
A higher proportion of males was observed in all except the Ger-
man databases, similarly to other published studies.10,12,35,36,41 The
larger proportion of women in the German databases could be related
to the characteristics of the population or to differences in NVAF inci-
dence. Other studies have reported that female patients are more
prevalent than males in those older than 75 or 80 years.45,464.3 | Baseline clinical characteristics
The clinical characteristics observed are comparable to similar studies
which used OAC naive or non‐naive NVAF patients.10,35,36 However,
there is heterogeneity of the demographics and baseline characteris-
tics across the databases. Different population coverage across the
databases, as well as differences in the prevalence of cardiovascular
diseases, could explain the observed differences.37
Previous cardiovascular events were the most frequent comorbid-
ity across all databases. The observed high proportion of previous car-
diovascular events in the German databases correlates with the high
percentage of cardiovascular problems observed in Germany.37 It
might also be related to the inclusion of data from medical specialists
in the German databases, whereas many of the other databases in this
study consider data from general practitioners only. In addition,
resource allocation for German sickness funds is based on the so‐
called morbidity‐oriented risk structure compensation scheme. There-
fore, all primary and secondary diagnoses must be coded to enable
appropriate calculations.47 The low prevalence in Mondriaan database
might be because only the least critical patients received DOAC from
primary care, as opposed to specialists.
The unexpectedly high proportion of CKD in the AOK and Bavar-
ian CD populations may be explained by a higher proportion of
patients with cardiovascular comorbidities or the inclusion of nonspe-
cific codes.4.4 | Concomitant use of potentially interacting
drugs
Concomitant use of drugs has been reported to be low and in very few
studies.35 Concomitant treatment with other anticoagulant drugs was
present in variable proportions, around 20% in the 2 German
IBÁÑEZ ET AL.2536databases, and EGB. This is of concern since these patients might have
a higher haemorrhagic risk. The presence of a high cardiovascular
comorbidity proportion in the German databases could partly explain
a higher use of medications. Furthermore, these 3 databases include
reimbursed drugs from specialist prescriptions. However, some of this
use could also be related to switching to anticoagulant therapy.
The concomitant use of cardiovascular drugs has been reported in
some studies, in particular antiplatelet drugs, between 11 and 30% of
users12,36; similarly, antiplatelet drugs were used in 10–18% of the
DOAC users in several databases in our study. Amiodarone, a strong
P‐glycoprotein inhibitor, was the most frequent potentially interacting
drug in several databases. Lower use has been described in the OAC
naïve Danish study.36
NSAIDs have been reported in similar or somewhat lower propor-
tions in other studies.12,35,41 Certain NSAIDs are available over the
counter in some countries, as well as on prescription. This, together
with differing prescriber behaviours treating pain or inflammatory con-
ditions, may account for some of the observed differences.484.5 | Dose adjustment related to age or changes in
renal function
The proportion of dose adjustment related to age or changes in renal
function was low (<1%). However, this result should be interpreted
with caution as data on renal function results were sparse (unregis-
tered data for renal failure up to 77.9%). In fact, a study aiming to
report CKD prevalence and recognition in a Swedish healthcare cohort
showed that registration of CKD diagnosis was suboptimal, with only
12% of affected patients having an ICD‐10 related diagnostic code.49
However, we suspect these unregistered values are more likely to
reflect less severe impairment. Moreover, not all reasons for dose
changes are registered in the different databases and we only consid-
ered those during the treatment episode. Therefore, patients appropri-
ately dosed at the index date, without any further dose changes, are
not considered as adjusted. The discrepancy between the proportion
of patients with changes in tablet strengths and the low proportion
of patients with age and CKD related adjustments might be due to
patients with an increase in tablet strength not being accounted for.
Other studies have reported about 20% patients receiving inappropri-
ate doses, most often too low (38%) or excessively high dose
(22%).14,154.6 | Strengths
The main strength of this study is the large number of patients provid-
ing real‐world data about incidence, concomitant use of potentially
interacting drugs and dose adjustments. In addition, the use of a stan-
dardized protocol across the different databases supports the inter-
pretation and comparability of results from selected countries.
Disease and drug codes were harmonized, the study results were
blinded and only shared with the whole consortium after each centre
had completed their analysis, avoiding some information bias andpromoting independent results. The consented and broad definition
of the inclusion criteria ensures the generalisability of the results as
all the new users with a diagnosis of NVAF were presumably included.
In addition, the performance of a sensitivity analysis excluding patients
with multiple potential DOAC indications gave similar results for most
of the main variables. This supports the results of the main analysis
with respect to closeness to real‐life DOAC use, since several indica-
tions might be present in addition to NVAF.4.7 | Limitations
There was large case mix in the databases, which made comparisons
between countries difficult. In addition, there are differences in popu-
lation coverage among the databases. Only 1 database includes the
total reference population (DNR), while others are considered repre-
sentative samples of the national populations when considering age,
sex and geographical distribution (UK/CPRD, Spain/BIFAP and
SIDIAP, France/EGB, Mondriaan). The inclusion of nonrepresentative
databases with population coverages under 90% (German databases)
must be considered when extending the results to the whole popula-
tion. Since we used prescription, dispensing or reimbursement data
that do not have complete information on actual drug intake, there
might have been certain degree of drug use misclassification, common
to all clinical studies, even randomized trials. In addition, drugs pre-
scribed by physicians, other than general practitioners, could be
missed when using prescribing databases as these are commonly gen-
eral practice databases.
A drop in the number of patients was observed in some databases
(Figure S1). This may be related to the fact that DOACs can be used
for a variety of diagnoses. Although some patients with NVAF may
have been lost in this process, the criteria ensure that we can be certain
all patients included in the analysis do indeed have NVAF.
Information on the indication associated with the prescription
might also be incomplete. For example, a definite linkage between
compound and indication is lacking in most of the databases hence,
we used the term potential indications. Additionally, some data
sources include data from hospital admissions and contacts (DNR),
while others include exclusively general practice encounters. Codes
used in diagnosis were not specifically validated in this study but
outcome validation has been performed in other studies showing
high validity.19,50-57 Laboratory values were not documented in
some databases so codes for renal impairment (including somewhat
nonspecific renal impairment codes) were used. This broad definition
may explain the high proportion of patients with CKD found in some
databases. Dose adjustment related to change in renal function and
age was only assessed if a change in dose was associated with a
change in renal function or in age; however, we did not assess if
changes in renal function were subsequently followed by changes
in dose. Moreover, a dose adjustment was defined as switching from
1 tablet strength to another of the same active substance. This def-
inition precludes assessing posology changes that may have taken
place without changing tablet strengths. Regarding potential
IBÁÑEZ ET AL. 2537interactions, lacking documentation of over the counter medications
might be relevant, in particular for some NSAIDS, low‐dose
acetylsalicylic acid (mainly pharmacodynamic interactions) and St
John's Wort (pharmacokinetic interaction).
In conclusion, this study shows an increased incidence of use of
DOACs related to NVAF in the study period across 6 European coun-
tries. In 2015, the incidence of DOAC use ranged from 8.7 per 10 000
in Spain to 27.6 per 10 000 in Denmark, with a higher incidence in
men than in women, especially in patients ≥75 years. Potential use
of contraindicated drugs, such as other anticoagulants, in some coun-
tries raises concerns about potential haemorrhagic risk. Finally, the
proportion of dose adjustment related to changes in renal function
or age deserves a more complete approach. The differences among
the countries might be explained by different national or regional rec-
ommendations, prescription patterns and characteristics of the
selected databases. Drug utilization studies based on several data-
bases across different countries using a standard protocol may help
to compare drug use and identify sources of variation, enabling health
care decisions and supporting the rational use of medicines.ACKNOWLEDGEMENTS
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